Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: bevacizumab|DRUG: Paclitaxel
Sponsor: Chugai Pharmaceutical